Dec 19 (Reuters) - Nurix Therapeutics Inc NRIX.O:
NURIX THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR NX-5948 FOR THE TREATMENT OF RELAPSED OR REFRACTORY WALDENSTROM’S MACROGLOBULINEMIA
NURIX THERAPEUTICS : ANTICIPATE SHARING ADDITIONAL CLINICAL DATA ABOUT ONGOING PHASE 1B EXPANSION COHORT IN 2025
Source text: ID:nGNX2tWLsG
Further company coverage: NRIX.O